Expression, purification, and characterization of engineered antibody CH2 and VH domains

Methods in Molecular Biology

Volumn 899, Issue , 2012, Pages 85-102

  Gong, Rui ^a   Chen, Weizao ^a   Dimitrov, Dimiter S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

CH2; Domain antibody; Engineered antibody domains; Library construction; Nanoantibody; Phage display; Stability; VH

Indexed keywords

IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY;

ARTICLE; GENETICS; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; METHODOLOGY; MUTATION; PARTICLE SIZE; PEPTIDE LIBRARY; PROTEIN ENGINEERING; PROTEIN STABILITY; PROTEIN TERTIARY STRUCTURE;

ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOGLOBULIN G; MUTATION; PARTICLE SIZE; PEPTIDE LIBRARY; PROTEIN ENGINEERING; PROTEIN STABILITY; PROTEIN STRUCTURE, TERTIARY;

EID: 84864135881     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-61779-921-1_6     Document Type: Article

References (20)

1. Kolmar H, Skerra A (2008) Alternative binding proteins get mature: Rivalling antibodies. FEBS J 275:2667
2. Skerra A (2007) Alternative non-Antibody scaffolds for molecular recognition. Curr Opin Biotechnol 18:295-304
3. Nygren PA, Skerra A (2004) Binding proteins from alternative scaffolds. J Immunol Methods 290:3-28
4. Binz HK, Amstutz P, Pluckthun A (2005) Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol 23:1257-1268
5. Hey T, Fiedler E, Rudolph R, Fiedler M (2005) Artificial, non-Antibody binding proteins for pharmaceutical and industrial applications. Trends Biotechnol 23:514-522
6. Holliger P, Hudson PJ (2005) Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23:1126-1136
7. Holt LJ, Herring C, Jespers LS, Woolven BP, Tomlinson IM (2003) Domain antibodies: Proteins for therapy. Trends Biotechnol 21:484-490
8. Saerens D, Ghassabeh GH, Muyldermans S (2008) Single-domain antibodies as building blocks for novel therapeutics. Curr Opin Pharmacol 8:600-608
9. Ward ES, Gussow D, Grif fi ths AD, Jones PT, Winter G (1989) Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli . Nature 341:544-546
10. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, Bendahman N, Hamers R (1993) Naturally occurring antibodies devoid of light chains. Nature 363:446-448
11. Muyldermans S, Cambillau C, Wyns L (2001) Recognition of antigens by single-domain antibody fragments: The super fl uous luxury of paired domains. Trends Biochem Sci 26:230-235
12. Feige MJ, Walter S, Buchner J (2004) Folding mechanism of the CH2 antibody domain. J Mol Biol 344:107-118
13. Gong R, Vu BK, Feng Y, Prieto DA, Dyba MA, Walsh JD, Prabakaran P, Veenstra TD, Tarasov SG, Ishima R, Dimitrov DS (2009) Engineered human antibody constant domains with increased stability. J Biol Chem 284: 14203-14210
14. Dimitrov DS (2009) Engineered CH2 domains (nanoantibodies). MAbs 1:26-28
15. Hackel BJ, Kapila A, Wittrup KD (2008) Picomolar af fi nity fi bronectin domains engineered utilizing loop length diversity, recursive mutagenesis, and loop shuf fl ing. J Mol Biol 381:1238-1252
16. Chen W, Zhu Z, Xiao X, Dimitrov DS (2009) Construction of a human antibody domain (VH) library. Methods Mol Biol 525:81-99, xiii
17. Xiao X, Feng Y, Vu BK, Ishima R, Dimitrov DS (2009) A large library based on a novel (CH2) scaffold: Identi fi cation of HIV-1 inhibitors. Biochem Biophys Res Commun 387:387-392
18. Humphrey W, Dalke A, Schulten K (1996) VMD: Visual molecular dynamics. J Mol Graph 14(33-38):27-38
19. Chen W, Zhu Z, Feng Y, Dimitrov DS (2008) Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers. Proc Natl Acad Sci USA 105:17121-17126
20. Hagihara Y, Mine S, Uegaki K (2007) Stabilization of an immunoglobulin fold domain by an engineered disul fi de bond at the buried hydrophobic region. J Biol Chem 282:36489-36495